Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7819186 | 0.89 | HTR2C (0.51) | HTR6 | |
| SCHEMBL23647501 | 0.83 | CYP1A2 (0.42) | HSD11B1CYP1A2ALDH1A1NR3C2L3MBTL1 | |
| SCHEMBL28376787 | 0.79 | KEAP1 (0.48) | HSD11B1ALDH1A1CA1CA2TSHR | |
| SCHEMBL23162797 | 0.79 | HSD11B1 (0.48) | HSD11B1LMNACA1CA2PTGS2 | |
| SCHEMBL4731653 | 0.77 | CYP1A2 (0.55) | CYP1A2ALDH1A1NR3C2L3MBTL1LMNA | |
| SCHEMBL2046628 | 0.76 | HSD11B1 (0.45) | HSD11B1ALDH1A1L3MBTL1MAPTCA1 | |
| SCHEMBL28370185 | 0.75 | CA12 (0.55) | CYP1A2ALDH1A1L3MBTL1LMNACA1 | |
| SCHEMBL9097473 | 0.75 | HSD11B1 (0.48) | HSD11B1LMNACA1CA2TSHR | |
| SCHEMBL23045663 | 0.75 | HSD11B1 (0.44) | HSD11B1ALDH1A1L3MBTL1LMNACA1 | |
| SCHEMBL4756861 | 0.75 | CA2 (0.48) | HSD11B1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051681-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2014-02-20 | — | — | US | disclosed |
| EP-2681206-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| US-8440652-B2 | MST1 kinase inhibitors and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| WO-2012121992-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| US-20120225857-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2012-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051681-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | MST1, STK10, STK3 | HSD11B1 1384/4885CYP1A2 4850/4885ALDH1A1 4258/4885 |
| US-20120225857-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | MST1, STK10, STK3 | HSD11B1 1384/4885CYP1A2 4850/4885ALDH1A1 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.